Suggested remit: To appraise the clinical and cost effectiveness of vorasidenib within its marketing authorisation for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6407
Provisional Schedule
- Committee meeting: 1:
- 18 September 2025
- Expected publication:
- 13 November 2025
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Stakeholders
- Companies sponsors
- Servier Laboratories (vorasidenib)
- Others
- Department of Health and Social Care
- Health Technology Wales (HTW)
- NHS England
- Patient carer groups
- Astro Brain Tumour Fund
- Brain Tumour Charity
- Brain Tumour Research
- International Brain Tumour Alliance
- Professional groups
- Association of British Neurologists
- Association of Cancer Physicians
- British Neuro-Oncology Society
- Cancer Research UK
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Society of British Neurological Surgeons
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 November 2024 | Topic selection |
| 19 November 2024 | Topic routing was discussed at the NICE Prioritisation Board in October 2024. The Board concluded that the topic was suitable for a Technology Appraisal. Please see HST checklist on the project documents tab for further details. |
| 19 November 2024 | Invitation to participate |
| 02 September 2024 - 30 September 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6407 |
| 02 September 2024 | In progress. Scoping commenced. |
| 30 January 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 January 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual